As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
BUSINESS
Astellas Revises Package Insert for Xtandi Following Confirmation of Clinical Benefits in PIII Study
Astellas Pharma announced on October 22 that it has revised the domestic package insert for Xtandi Capsules 40 mg (enzalutamide), a treatment for castration-resistant prostate cancer (CRPC). The company deleted the statement “The efficacy and safety of this drug have…
To read the full story
BUSINESS
- Eisai to Unify Global HR Framework by 2029 to Bolster Leqembi Growth
November 25, 2025
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Sanofi Seeks Age 60+ Access as Japan Plans NIP Addition of Efluelda for 75+
November 25, 2025
- Kyowa Kirin Begins Japan PIII Trial of Infigratinib for Achondroplasia
November 25, 2025
- Expert Expects New 21-Valent Pneumococcal Shot Capvaxive to Curb Invasive Disease
November 25, 2025
Japan is set to tighten reimbursement rules for regenerative medicine products granted conditional, time-limited approval, with Central Social Insurance Medical…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…